Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - mometasone furoate, quantity: 1 mg/g - cream - excipient ingredients: aluminium starch octenylsuccinate; white soft paraffin; titanium dioxide; phosphoric acid; purified water; white beeswax; hexylene glycol; hydrogenated soy phosphatidylcholine - novasone cream, ointment and lotion are indicated for short-term (up to four (4) continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis and atopic dermatitis. novasone lotion is also suitable for short-term use for scalp psoriasis and seborrhoeic dermatitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - mometasone furoate, quantity: 1 mg/g - cream - excipient ingredients: hexylene glycol; white beeswax; purified water; aluminium starch octenylsuccinate; phosphoric acid; titanium dioxide; white soft paraffin; hydrogenated soy phosphatidylcholine - elocon alcohol free cream ointment and lotion are indicated for short-term up to four (4) continuous weeks relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis and atopic dermatitis. elocon lotion is also suitable for short-term use for scalp psoriasis and seborrhoeic dermatitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - mometasone furoate -

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - mometasone furoate, quantity: 1 mg/g - ointment - excipient ingredients: hexylene glycol; purified water; phosphoric acid; white beeswax; white soft paraffin; propylene glycol monostearate - the short term (up to four continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis & atopic dermatitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - mometasone furoate, quantity: 1 mg/g - ointment - excipient ingredients: white soft paraffin; propylene glycol monostearate; purified water; hexylene glycol; white beeswax; phosphoric acid - the short term (up to four continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis & atopic dermatitis.

Malta - English - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - mometasone furoate - ointment - mometasone furoate 0.1 % (w/w) - corticosteroids, dermatological preparations

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - mometasone furoate -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - mometasone furoate -

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate cream usp, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older. mometasone furoate cream is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. teratogenic effects: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. mometasone furoate also caused dystocia and related complications when administered to rats during the end of pregnancy. in mice, mometasone furoate caused cleft palate at subcutaneous doses of 60 mcg/kg and above. fetal survival was reduced at 180 mcg/kg. no toxicity was observed at 20 mcg/kg. (doses of 20 mcg/kg, 60 mcg/kg, and 180 mcg/kg in the mouse are approximately 0.01 times, 0.02 times, and 0.05 times the estimated maximum clinical topical dose from mometasone furoate cream on a mcg/m 2 basis.) in rats, mometasone furoate produced umbilical hernias at topical doses of 600 mcg/kg and above. a dose of 300 mcg/kg produced delays in ossification, but no malformations. (doses of 300 mcg/kg and 600 mcg/kg in the rat are approximately 0.2 times and 0.4 times the estimated maximum clinical topical dose from mometasone furoate cream on a mcg/m 2 basis.) in rabbits, mometasone furoate caused multiple malformations (e.g., flexed front paws, gallbladder agenesis, umbilical hernia, hydrocephaly) at topical doses of 150 mcg/kg and above (approximately 0.2 times the estimated maximum clinical topical dose from mometasone furoate cream on a mcg/m 2 basis). in an oral study, mometasone furoate increased resorptions and caused cleft palate and/or head malformations (hydrocephaly and domed head) at 700 mcg/kg. at 2800 mcg/kg most litters were aborted or resorbed. no toxicity was observed at 140 mcg/kg. (doses at 140 mcg/kg, 700 mcg/kg, and 2800 mcg/kg in the rabbit are approximately 0.2 times, 0.9 times, and 3.6 times the estimated maximum clinical topical dose from mometasone furoate cream on a mcg/m 2 basis.) when rats received subcutaneous doses of mometasone furoate throughout pregnancy or during the later stages of pregnancy, 15 mcg/kg caused prolonged and difficult labor and reduced the number of live births, birth weight, and early pup survival. similar effects were not observed at 7.5 mcg/kg. (doses of 7.5 mcg/kg and 15 mcg/kg in the rat are approximately 0.005 times and 0.01 times the estimated maximum clinical topical dose from mometasone furoate cream on a mcg/m 2 basis.) systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. it is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. because many drugs are excreted in human milk, caution should be exercised when mometasone furoate cream is administered to a nursing woman. mometasone furoate cream may be used with caution in pediatric patients 2 years of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established. since safety and efficacy of mometasone furoate cream have not been established in pediatric patients below 2 years of age, its use in this age group is not recommended. in a pediatric trial, 24 atopic dermatitis subjects, of whom 19 subjects were age 2 to 12 years, were treated with mometasone furoate cream once daily. the majority of subjects cleared within 3 weeks. mometasone furoate cream caused hpa axis suppression in approximately 16% of pediatric subjects ages 6 to 23 months, who showed normal adrenal function by cortrosyn test before starting treatment, and were treated for approximately 3 weeks over a mean body surface area of 41% (range 15% to 94%). the criteria for suppression were: basal cortisol level of ≤5 mcg/dl, 30-minute post-stimulation level of ≤18 mcg/dl, or an increase of <7 mcg/dl. follow-up testing 2 to 4 weeks after trial completion, available for 5 of the subjects, demonstrated suppressed hpa axis function in 1 subject, using these same criteria. long-term use of topical corticosteroids has not been studied in this population [see clinical pharmacology (12.2)]. because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of hpa axis suppression and cushing's syndrome when they are treated with topical corticosteroids. they are, therefore, also at greater risk of adrenal insufficiency during and/or after withdrawal of treatment. pediatric patients may be more susceptible than adults to skin atrophy, including striae, when they are treated with topical corticosteroids. pediatric patients applying topical corticosteroids to greater than 20% of body surface are at higher risk of hpa axis suppression. hpa axis suppression, cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. mometasone furoate cream should not be used in the treatment of diaper dermatitis. clinical studies of mometasone furoate cream included 190 subjects who were 65 years of age and over and 39 subjects who were 75 years of age and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. however, greater sensitivity of some older individuals cannot be ruled out.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate cream usp, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older. mometasone furoate cream is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. teratogenic effects: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. mometasone furoate also caused dystocia and related complications when administered to rats during the end of pregnancy. in mice, mometasone furoate caused cleft palate at subcutaneous doses of 60 mcg/kg and above. fetal survival was reduced at 180 mcg/kg. no toxicity was observed at 20 mcg/kg. (doses of 20 mcg/kg, 60 mcg/kg, and 180 mcg/kg in the mouse are approximately 0.01 times, 0.02 times, and 0.05 times the estimated maximum clinical topical dose from mometasone furoate cream on a mcg/m2 basis.) in rats, mometasone furoate produced umbilical hernias at topical doses of 600 mcg/kg and above. a dose of 300 mcg/kg produced delays in ossification, but no malformations. (doses of 300 mcg/kg and 600 mcg/kg in the rat are approximately 0.2 times and 0.4 times the estimated maximum clinical topical dose from mometasone furoate cream on a mcg/m2 basis.) in rabbits, mometasone furoate caused multiple malformations (e.g., flexed front paws, gallbladder agenesis, umbilical hernia, hydrocephaly) at topical doses of 150 mcg/kg and above (approximately 0.2 times the estimated maximum clinical topical dose from mometasone furoate cream on a mcg/m2 basis). in an oral study, mometasone furoate increased resorptions and caused cleft palate and/or head malformations (hydrocephaly and domed head) at 700 mcg/kg. at 2800 mcg/kg most litters were aborted or resorbed. no toxicity was observed at 140 mcg/kg. (doses at 140 mcg/kg, 700 mcg/kg, and 2800 mcg/kg in the rabbit are approximately 0.2 times, 0.9 times, and 3.6 times the estimated maximum clinical topical dose from mometasone furoate cream on a mcg/m2 basis.) when rats received subcutaneous doses of mometasone furoate throughout pregnancy or during the later stages of pregnancy, 15 mcg/kg caused prolonged and difficult labor and reduced the number of live births, birth weight, and early pup survival. similar effects were not observed at 7.5 mcg/kg. (doses of 7.5 mcg/kg and 15 mcg/kg in the rat are approximately 0.005 times and 0.01 times the estimated maximum clinical topical dose from mometasone furoate cream on a mcg/m2 basis.) systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. it is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. because many drugs are excreted in human milk, caution should be exercised when mometasone furoate cream is administered to a nursing woman. mometasone furoate cream may be used with caution in pediatric patients 2 years of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established. since safety and efficacy of mometasone furoate cream have not been established in pediatric patients below 2 years of age, its use in this age group is not recommended. in a pediatric trial, 24 atopic dermatitis subjects, of whom 19 subjects were age 2 to 12 years, were treated with mometasone furoate cream once daily. the majority of subjects cleared within 3 weeks. mometasone furoate cream caused hpa axis suppression in approximately 16% of pediatric subjects ages 6 to 23 months, who showed normal adrenal function by cortrosyn test before starting treatment, and were treated for approximately 3 weeks over a mean body surface area of 41% (range 15% to 94%). the criteria for suppression were: basal cortisol level of ≤5 mcg/dl, 30-minute post-stimulation level of ≤18 mcg/dl, or an increase of <7 mcg/dl. follow-up testing 2 to 4 weeks after trial completion, available for 5 of the subjects, demonstrated suppressed hpa axis function in 1 subject, using these same criteria. long-term use of topical corticosteroids has not been studied in this population [see clinical pharmacology (12.2)]. because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of hpa axis suppression and cushing's syndrome when they are treated with topical corticosteroids. they are, therefore, also at greater risk of adrenal insufficiency during and/or after withdrawal of treatment. pediatric patients may be more susceptible than adults to skin atrophy, including striae, when they are treated with topical corticosteroids. pediatric patients applying topical corticosteroids to greater than 20% of body surface are at higher risk of hpa axis suppression. hpa axis suppression, cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. mometasone furoate cream should not be used in the treatment of diaper dermatitis. clinical studies of mometasone furoate cream included 190 subjects who were 65 years of age and over and 39 subjects who were 75 years of age and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. however, greater sensitivity of some older individuals cannot be ruled out.